Cabaletta Bio, Inc. CABA

CABA Company Overview

Cabaletta Bio, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing engineered cell therapies for autoimmune diseases. The company operates within the biotechnology and immunology sectors, with a primary emphasis on precision cellular immunotherapies designed to selectively reset or eliminate pathogenic immune cells. Cabaletta Bio’s core technology platforms are centered on chimeric antigen receptor (CAR) T-cell therapies and engineered T-cell approaches intended to treat autoimmune disorders with high unmet medical need. Its lead programs target diseases such as myositis, systemic sclerosis, lupus nephritis, generalized myasthenia gravis, and other B cell-mediated autoimmune conditions.

The company’s primary revenue drivers remain research and development activities and capital raised through equity financing, as Cabaletta Bio has not yet commercialized products. A major strategic differentiator is its focus on applying CAR T-cell technologies—traditionally developed for oncology—to autoimmune diseases using its “deep reset” therapeutic concept aimed at durable immune reprogramming. Cabaletta Bio was founded in 2017 and emerged from research conducted at the University of Pennsylvania, particularly work associated with advances in cellular immunotherapy and B-cell targeting technologies. The company became publicly traded on the Nasdaq under the ticker CABA in 2019.